

August 13th, 2021

COM-2021-037

Dear provider of healthcare-related services,

On August 12th, 2021, the Food and Drug Administration (FDA) amended the Emergency Use Authorizations (EUAs) for both the Pfizer-BioNTech and the Moderna COVID-19 vaccine to allow for the use of an additional dose in certain immunocompromised individuals (solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise). The authorizations for these vaccines have been amended to allow for a third dose to be administered at least 28 days following the two-dose regimen of the same vaccine. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) is meeting to discuss clinical recommendations for this population. Of note, this amendment does not apply to people who are not immunocompromised.

For additional information, you can refer to:

1. The [CDC Advisory Committee on Immunization Practices \(ACIP\)'s website](#) has the ACIP recommendations for this immunocompromised population and links to the meeting.
2. The [FDA's COVID-19 Resources for Health Professionals](#)
3. [Pfizer Vaccine Fact Sheet for Healthcare Providers Administering Vaccine](#)
4. [Moderna Vaccine Fact Sheet for Healthcare Providers Administering Vaccine](#)

The situation with the COVID-19 pandemic is dynamic and continuously changing. We strongly encourage the frequent revision of updated information provided by the FDA and the CDC to assure that your practices are consistent with the most actualized information.

PharmPix is committed to our members' health and wellness. It is our priority to offer high-quality services and support practices for health promotion and diseases prevention. If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 137. Also, you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

Regards,

Clinical Department

References:

1. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. U.S. Food and Drug Administration. (2021). Retrieved 13 August 2021, from <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised>

